Zhengye Biotechnology Holding (ZYBT) Invested Capital (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Invested Capital for 3 consecutive years, with $53.8 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Invested Capital fell 12.01% year-over-year to $53.8 million in Q4 2025; TTM through Dec 2025 was $53.8 million, a 12.01% decrease from a year earlier, with the FY2025 full-year figure at $53.8 million, down 12.01% from the prior year.
• Invested Capital was $53.8 million for Q4 2025 at Zhengye Biotechnology Holding, down from $62.3 million in the prior quarter.
• Over five years, Invested Capital peaked at $62.3 million in Q2 2025 and troughed at $53.8 million in Q4 2025.
• A 3-year average of $59.2 million and a median of $60.4 million in 2023 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital increased 2.54% in 2024 and declined 12.01% in 2025, its largest moves.
• Over 3 years, Invested Capital stood at $59.6 million in 2023, then climbed by 2.54% to $61.1 million in 2024, then slipped by 12.01% to $53.8 million in 2025.
• The last three Invested Capital figures came in at $53.8 million (Q4 2025), $62.3 million (Q2 2025), and $61.1 million (Q4 2024), per Business Quant data.